DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
DiaMedica received FDA feedback requesting additional nonclinical reproductive toxicity data for DM199 to support a U.S. IND for preeclampsia treatment. The company believes it can leverage previous rat study data by initiating a new pharmacokinetic and activity study to demonstrate sufficient exposure and enzymatic effect.
Key figures
- Drug Name
- DM199 (rinvecalinase alfa)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.